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Summary
 Background Quality of life (QoL) is deﬁ ned as “a patient’s subjective evaluation of his life sit-
uation”. QoL evaluation is carried out by means of generic and speciﬁ c question-
naires. Generic QoL questionnaires generally evaluate a patient’s overall condition 
regardless of his disease. Speciﬁ c QoL questionnaires are designed to evaluate a 
patient’s overall condition for a particular type of disease.
 Aim The study analyses the effect of selected psychosocial and health aspects on qual-
ity of life in patients with multiple myeloma and malignant lymphoma undergo-
ing autologous progenitor stem cell transplantation.
 Materials/Methods The total number of respondents undergoing transplantation between 2001 and 
2003 was 56:32 respondents (18 male and 14 female) with multiple myeloma, 
and 24 respondents (11 male and 13 female) with malignant lymphoma. The 
average age of patients with multiple myeloma was 60 years and the average age 
of patients with malignant lymphoma was 44.5 years. The Czech version of the 
international generic European Quality of Life Questionnaire, Version EQ-5D, 
was used. The effect of selected psychosocial and health aspects (age, sex, level 
of education, marital status, number of associated diseases, smoking abuse, reli-
gion, type of disease and time since the transplantation) on quality of life in pa-
tients was determined by means of analysis of variance.
 Results The above-mentioned aspects proved statistically signiﬁ cant dependence of qual-
ity of life on age, smoking abuse in patients with multiple myeloma and on type 
of disease. EQ-5D score (dimensions of quality of life) and EQ-5D VAS (subjec-
tive health condition) signiﬁ cantly decrease with increasing age in both groups 
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BACKGROUND
Quality of life (QoL) is deﬁ ned as “a patient’s 
subjective evaluation of his life situation” [1–3]. 
The QoL term contains information on an indi-
vidual’s physical, psychological, social and spir-
itual condition [4,5]. QoL evaluation is carried 
out by means of generic and speciﬁ c question-
naires [2,3]. Generic QoL questionnaires gener-
ally evaluate a patient’s overall condition regard-
less of his disease. Speciﬁ c QoL questionnaires 
are designed to evaluate a patient’s overall con-
dition for a particular type of disease. Modules 
are often used with these speciﬁ c questionnaires. 
These modules are focused on speciﬁ c symp-
toms and complaints in a particular type of dis-
ease [2,3].
AIMS OF STUDY
1. To analyse the effect of selected psycho-
social and health aspects on QoL in patients 
with multiple myeloma and malignant lym-
phoma undergoing autologous PSCT at 
the Department of Clinical Haematology 
of the Department of Medicine of Charles 
University Hospital in Hradec Kralove, Czech 
Republic.
2. To evaluate global QoL in patients with mul-
tiple myeloma and malignant lymphoma un-
dergoing autologous PSCT at the Department 
of Clinical Haematology of the Department 
of Medicine of Charles University Hospital in 
Hradec Kralove, Czech Republic.
Design of study
The study is cross-sectional and retrospective. It is 
based on data obtained during the year 2004 (from 
1 September to 31 December) in 56 patients with 
multiple myeloma and malignant lymphoma un-
dergoing autologous PSCT between 2001 and 2003. 
The study was approved by the Ethics Commission 
of the Charles University Hospital and Medical 
Faculty in Hradec Kralove, Czech Republic.
The study analyses the effect of selected psycho-
social and health aspects on QoL in patients 
with multiple myeloma and malignant lympho-
ma undergoing autologous PSCT in the period 
of 2001–2003, some of the results of which have 
already been published [2]. We continued to 
analyse and compare the effect of selected as-
pects on QoL in patients with multiple myelo-
ma and malignant lymphoma undergoing au-
tologous PSCT.
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of patients and with smoking abuse in patients with multiple myeloma, and are 
signiﬁ cantly higher in patients with malignant lymphoma. The effect of other 
aspects on quality of life was not proven as statistically signiﬁ cant. The quality of 
life in patients with multiple myeloma undergoing autologous progenitor stem 
cell transplantation is at a lower level (mean EQ-5D score 68.9%, mean EQ-5D 
VAS 66.6%) than in patients with malignant lymphoma after the transplanta-
tion (mean EQ-5D score 82.7%, mean EQ-5D VAS 76.7%) at the Department 
of Clinical Haematology of the Department of Medicine of Charles University 
Hospital in Hradec Kralove, Czech Republic.
 Conclusion The global quality of life in our patients with multiple myeloma and malignant 
lymphoma undergoing autologous progenitor stem cell transplantation is at a 
good level.
 Key words quality of life • autologous progenitor stem cell transplantation • multiple myeloma • 
malignant lymphoma
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MATERIALS AND METHODS
Group characteristics
The total number of patients with multiple my-
eloma and malignant lymphoma undergoing 
autologous PSCT at the Department of Clinical 
Haematology of the Department of Medicine of 
Charles University Hospital in Hradec Kralove, 
Czech Republic, between 2001 and 2003 was 
122 (70 patients with multiple myeloma and 52 
patients with malignant lymphoma). The total 
number of respondents was 80 (36 patients died 
and 6 patients underwent retransplantation). 
The return rate of questionnaires was 70% (56 
respondents: 32 respondents (18 male and 14 fe-
male) with multiple myeloma and 24 respondents 
(11 male and 13 female) with malignant lympho-
ma) and we could evaluate 100% of them. The 
average age of patients with multiple myeloma 
was 60 years. The average age of patients with ma-
lignant lymphoma was 44.5 years. Table 1 shows 
the representation of respondents with multiple 
myeloma and malignant lymphoma undergoing 
autologous PSCT between 2001 and 2003.
Instrument
The Czech version of the international generic 
EuroQol EQ-5D Questionnaire was used in the 
study [2,6]. This questionnaire evaluates two in-
dicators, objective and subjective. The objective 
indicator includes ﬁ ve dimensions of QoL: mo-
bility, self-care, usual activities, pain/discomfort, 
anxiety/depression. Three kinds of answers which 
express the degree of complaints are offered for 
each question (no complaints, mild complaints, 
severe complaints). In total 243 (35) combina-
tions of health condition exist. The outcome is 
the EQ-5D score (dimensions of QoL) having a 
value from 0 to 1 (0 – the worst health condition, 
1 – the best health condition). The subjective in-
dicator includes a visual analogous scale (a val-
ue of 100 – the best health condition, a value of 
0 – the worst health condition). The respond-
ent marks his subjectively perceived health con-
dition on a ‘thermometer’ scale. The outcome is 
EQ-5D VAS (subjective health condition) which 
has values from 0 to 100.
A questionnaire with a covering letter, in which 
the whole project was explained, together with 
a stamped envelope were posted to the respond-
ent’s address.
Data analysis
The evaluation of questionnaires was carried out by 
means of descriptive analysis in accordance with the 
European Quality of Life Group Method [6]. The 
independent variables were age, sex, level of educa-
tion, marital status, number of associated diseases, 
smoking abuse, religion and time since PSCT. The 
dependent variables were EQ-5D score (dimensions 
of QoL) and EQ-5D VAS (subjective health condi-
tion). The effect of selected aspects of QoL of pa-
tients was evaluated by means of analysis of variance 
(ANOVA). StatSoft STATISTICA Base 7.1 software 
was used for complete evaluation of dates. The val-
ue p<0.05 was considered signiﬁ cant.
RESULTS
The above-mentioned aspects proved statistically 
signiﬁ cant dependence of EQ-5D score and EQ-
5 VAS on age (in both cases p<0.01), statistically 
signiﬁ cant dependence of EQ-5D score and EQ-
5 VAS on smoking abuse in patients with multi-
ple myeloma (in both cases p<0.05) and statis-
tically signiﬁ cant dependence of EQ-5D score 
and EQ-5 VAS on type of disease (in both cases 
p<0.01). EQ-5D score (dimensions of QoL) and 
EQ-5D VAS (subjective health condition) sig-
niﬁ cantly decrease with increasing age in both 
groups of patients (Figures 1, 2). They are sig-
niﬁ cantly higher in non-smokers in the multiple 
myeloma group (Figure 3). They are signiﬁ cant-
ly higher in patients with malignant lymphoma 
(Figure 4, Table 2). The effect of other aspects 
on QoL (EQ-5D score and EQ-5D VAS) was not 
proven as statistically signiﬁ cant.
The global QoL in patients with multiple myelo-
ma undergoing autologous PSCT is lower (mean 
Type of disease Year 2001 Year 2002 Year 2003 Total number
Multiple Myeloma 10 8 14 32
Malignant Lymphoma 8 6 10 24
Table 1. Number of respondents with multiple myeloma and malignant lymphoma undergoing autologous PSCT between 2001 and 2003.
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EQ-5D score 68.9%, mean EQ-5D VAS 66.6%) 
than in patients with malignant lymphoma un-
dergoing autologous PSCT (mean EQ-5D score 
82.7%, mean EQ-5D VAS 76.7%).
DISCUSSION
Three main outcomes follow from our study:
1. The effect of age on the global QoL in both 
patients groups undergoing autologous PSCT 
has been proved.
Our results show that a lower QoL correlates with 
increasing age of patients who underwent HSCT. 
De Souza [7], Heinonen [8,9], Chiodi [10], 
Wang [11], Wong [12], Andrykowski [13] and 
Zittoun [14] discovered a similar trend in their 
studies. De Souza [7] points out in his longitu-
dinal study conducted in a group of 26 patients 
(13 patients who underwent BMT and 13 patients 
who underwent SCT) the fact that with increas-
ing age a number of associated diseases can oc-
cur (polymorbidity) in both groups of these pa-
tients. These diseases reduce QoL. Choidi [10] 
also agrees with this opinion in his transversal 
study conducted in a group of 244 patients with 
haematological malignancies who underwent al-
logeneic BMT. He also points out the fact that 
in addition to polymorbidity and negative effect 
of chronic graft-versus-host disease (cGVHD) 
on a lower QoL in patients with increasing age 
should be stressed. Wang [11], Wong [12] and 
Andrykowski [13] also agree about the inﬂ u-
ence of cGVHD on lower QoL in patients with 
increasing age. Zittoun [14] discovered another 
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Figure 1. Dependence of EQ-5D score and EQ-5D VAS on individual 
age groups in patients with multiple myeloma undergoing 
autologous PSCT between 2001 and 2003 (n=32, p<0.01).
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Figure 2. Dependence of EQ-5D score and EQ-5D VAS on individual 
age groups in patients with malignant lymphoma undergoing 
autologous PSCT between 2001 and 2003 (n=24, p<0.01).
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Figure 3. Dependence of EQ-5D score and EQ-5D VAS on smoking 
abuse in patients with multiple myeloma undergoing autologous 
PSCT between 2001 and 2003 (n=32, p<0.01).
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Figure 4. Dependence of EQ-5D score and EQ-5D VAS on type of 
disease in patients undergoing autologous PSCT between 2001 
and 2003 (n=56, p<0.01).
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interesting piece of information in his transversal 
study conducted in a group of 179 patients with 
haematological malignancies who underwent 
HSCT. He points out that increasing overall fa-
tigue and emotional complaints which decrease 
QoL correlate with increasing age. So [15] also 
discovered an interesting piece of information 
in his transversal study conducted in a group of 
157 patients with haematological malignancies 
who underwent BMT. He proved a high degree 
of overall fatigue in patients over the age of 50 
with associated diseases. Another author who 
agrees with Zittoun’s [14] and So’s [15] opin-
ions is Saleh [16]. He conducted a transversal 
study in a group of 41 patients who underwent 
BMT. This author [16] points out that in patients 
with an increasing number of associated diseas-
es there is a lower overall physical condition and 
this means lower QoL.
Kouroukise’s pilot study of 2004 brought inter-
esting information [17]. The group of respond-
ents comprised 76 patients with non-Hodgkin’s 
lymphoma. To test the respondents, the author 
produced a questionnaire on QoL which covered 
6 domains of QoL, namely physical aspects, psy-
chological aspects, social and economic aspects, 
toxicity and the whole appearance with a total 
of 29 questions. The author [17] compared two 
groups of patients, the ﬁ rst group with patients 
up to 65 years of age and the second one over 65 
years of age, with no statistically signiﬁ cant effect 
of age on QoL in this group.
2. The effect of smoking abuse on global QoL in 
groups of patients with multiple myeloma un-
dergoing autologous PSCT has been proved.
In the cohort of patients with multiple myeloma 
undergoing autologous PSCT we proved a lower 
global QoL in smokers in comparison with non-
smokers or former smokers. Chang [18] found 
an opposite trend in his longitudinal follow-up 
of patients with chronic myeloid leukaemia un-
dergoing allogeneic HSCT, in whom the effect 
of alcohol and smoking abuse on QoL was ob-
served. The group consisted of 114 patients. The 
author did not prove in his study an effect of al-
cohol and smoking abuse on QoL in this group 
of patients [18]. Slovacek [2] did not prove an 
effect of smoking abuse on global QoL in pa-
tients undergoing HSCT in his cross-sectional 
Dimension of quality of life Level of evaluation Malignant lymphoma Multiple myeloma
Number of respondents abs. rel abs. rel.
Mobility no troubles  17 70.8%  13 41%
with troubles  7 29.2%  19 59%
immobile  0  0
Self-care no troubles  22 91.7%  26 81.2%
with troubles  2 8.3%  6 18.8%
incapable  0  0
Usual activities no troubles  17 70.8%  6 18.8%
with troubles  6 25.0%  26 81.2%
incapable  1 4.2%  0
Pain/discomfort none  16 66.7%  9 28.1%
substantial  8 33.3%  22 68.8%
extreme  0  1 3.1%
Anxiety /depression none  18 75.0%  13 41%
substantial  5 20.8%  19 59%
extreme  1 4.2%  0
Number of respondents  24  32
Table 2. Comparison of respondents with multiple myeloma and malignant lymphoma undergoing autologous PSCT according to the 
level of troubles and the type of disease.
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study conducted in a group of 71 patients un-
dergoing HSCT.
3. The effect of type of disease on global QoL in 
patients undergoing autologous PSCT has been 
proved.
We conﬁ rmed in our cross-sectional follow-up a 
statistically signiﬁ cant dependence of global QoL 
in patients undergoing autologous PSCT on the 
type of disease. We found a lower global QoL in 
the cohort of patients with multiple myeloma un-
dergoing autologous PSCT (EQ-5D score 68.9%, 
EQ-5D VAS 66.6%) in comparison with the co-
hort of patients with malignant lymphoma un-
dergoing autologous PSCT (EQ-5D score 82.7%, 
EQ-5D VAS 76.7%). Prevailing complaints in the 
cohort of patients with multiple myeloma are: 1. 
regular activity with complaints 81.2% (26/32 re-
spondents), 2. medium serious pain / discomfort 
68.8% (22/32 respondents), 3. movement with 
complaints 59% (19/32 respondents), 4. medi-
um serious anxiety / depression 59% (19/32 re-
spondents). Prevailing complaints in the cohort 
of patients with malignant lymphoma are: 1. me-
dium serious pain/discomfort 33.3% (8/24 re-
spondents), 2. movement with complaints 29.2% 
(7/24 respondents), regular activity with com-
plaints 25% (6/24 respondents), medium seri-
ous anxiety/depression 20.8% (5/24 respond-
ents). Poulos [19] revealed a similar trend in 
his descriptive study of the year 2001 in a group 
of patients with multiple myeloma which com-
prised 346 patients. The author observed an ef-
fect of pain and mood disturbances on QoL in 
these patients. The study results prove that 29% 
of patients with multiple myeloma feel a pain 
of moderate to strong intensity. Furthermore, 
the study indicates a signiﬁ cant association be-
tween intensity of pain and mood disturbance. 
Moreover, tumour pain and mood disturbances 
are found to be signiﬁ cant predictors of QoL in 
this group of patients [19]. Holzner (20) com-
pared in his cross-sectional study a group of 418 
patients subdivided into groups according to type 
of oncological disease: 1st group, patients with 
Hodgkin’s lymphoma; 2nd group, female patients 
with breast carcinoma; 3rd group, patients with 
chronic lymphatic leukaemia. These patients 
were not treated with HSCT. Holzner [20] did 
not prove in his study signiﬁ cant differences in 
QoL according to the type of disease. Moreover, 
comparing both questionnaires, he did not con-
ﬁ rm signiﬁ cant differences in evaluation of QoL 
[20]. Van Agthoven [21] compared QoL in his 
cross-sectional study of a group of 91 patients with 
non-Hodgkin’s and Hodgkin’s lymphoma treated 
with autologous BMT and autologous PSCT. The 
group of 91 patients was subdivided into three 
mixed groups. He conﬁ rmed in his study a low-
er QoL in patients with non-Hodgkin’s lympho-
ma undergoing autologous PSCT or autologous 
BMT in comparison with patients with Hodgkin’s 
lymphoma undergoing autologous PSCT or au-
tologous BMT. Furthermore, the author did not 
prove differences in QoL between the groups 
in dependence on the type of transplantation 
(the same QoL in both groups of patients after 
autologous PSCT or BMT) [21]. Mounier [22] 
carried out a similar follow-up. In his cross-sec-
tional study, he compared QoL in patients with 
non-Hodgkin’s lymphoma treated with high-dose 
chemotherapy and consequently with autologous 
BMT and QoL in patients with non-Hodgkin’s 
lymphoma treated with sequential chemothera-
py. The group comprised 541 patients with non-
Hodgkin’s lymphoma in the ﬁ rst complete re-
mission, which was divided into two subgroups 
of patients: 1. patients with non-Hodgkin’s lym-
phoma treated with high-dose chemotherapy and 
autologous BMT, 2. patients with non-Hodgkin’s 
lymphoma treated with sequential chemothera-
py. The results of Mounier’s study reveal a high-
er QoL in patients with non-Hodgkin’s lympho-
ma treated with high-dose chemotherapy and 
autologous BMT compared with patients with 
non-Hodgkin’s lymphoma treated with sequen-
tial chemotherapy [22].
CONCLUSIONS
It is common in clinical practice to evaluate a 
patient’s health condition and the success of 
the treatment based only on one type of mark-
er, most often by means of somatic, laboratory 
or detecting markers. But the trend in modern 
clinical medicine is to evaluate a patient’s health 
condition in a more complex way, using other 
aspects. QoL means more dimensional evalua-
tion of a number of life aspects. Different aspects 
can be affected in a different way in a different 
phase of the disease and its treatment. That is 
why this information enriches our knowledge 
concerning a patient’s needs and it can signiﬁ -
cantly contribute to the improvement of medical 
treatment. It can also help us to reveal the mech-
anisms which modify the origin and the course 
of disease (23,24).
As is known, our study together with the study 
of the Czech Myeloma Society of the year 2002, 
which evaluated QoL and tolerance of sustained 
Original Paper Rep Pract Oncol Radiother, 2007; 12(2): 101-108
106
therapy in patients with multiple myeloma, is 
one of several Czech studies dealing with QoL 
in haematooncological patients [24]. Our study 
reveals global QoL in patients with multiple mye-
loma and malignant lymphoma after autologous 
PSCT. In the future, we would like to continue 
this study and carry on a prospective study which 
would longitudinally evaluate health-related qual-
ity of life (HRQoL) and which would be more 
focussed on characteristics of particular diseas-
es, on methods of pretransplantation procedure 
and on the type of transplantation.
We are also aware that our study may be limited 
by several other factors: 1. The study deals only 
with the effect of selected aspects on global QoL. 
We could add a few other aspects. But we decid-
ed on these aspects because patients were able 
and willing to provide this information in a ret-
rospectively and anonymously carried out study. 
2. In the study we used only generic Euro Qol 
EQ-5D for evaluation of global QoL in our pa-
tients. We decided on its evaluation because our 
patients were able and willing to complete only 
this questionnaire. Our patients emphasized that 
this questionnaire was very intelligible and espe-
cially brief. We could use the original Czech ver-
sion of the FACT-G Questionnaire or the EORTC 
QLQ-C30 Questionnaire, but our patients were 
against completing one of these questionnaires. 
The patients emphasized that these question-
naires are very comprehensive and time-consum-
ing. 3. There was a relatively small group of all 
our patients in both patient groups undergoing 
autologous PSCT. 4. There is little information 
about effect of selected aspects (especially reli-
gion, smoking abuse and level of education) on 
QoL in patients undergoing autologous PSCT in 
literature reviews for extensive discussion.
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